Merck KGaA’s $11.3B Acquisition of Bio-Techne: What Cross-Border M&A Leaders Must Learn Now
Merck KGaA’s $11.3 billion acquisition of Bio-Techne marks the largest cross-border life sciences deal of the quarter, setting a new benchmark for due diligence rigour and post-merger integration strategy. M&A directors and CFOs should treat this transaction as a strategic reference point for cross-Atlantic deal-making in 2025.